Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease

Congestive Heart Failure

Volumn 16, Issue 3, 2010, Pages 111-117

  Giles, Thomas D ^a   Elkayam, Uri ^b   Bhattacharya, Mondira ^c   Perez, Alfonso ^c   Miller, Alan B ^d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDEMA; FEMALE; HEART ARREST; HEART FAILURE; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; WEIGHT GAIN;

CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; GLYBURIDE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; SYSTOLE; THIAZOLIDINEDIONES;

EID: 77953995258     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00154.x     Document Type: Article

References (19)

1. Nesto RW, Bell D, Bonow RO. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948.
2. Tang WH, Francis GS, Hoogwerf BJ. Fluid retention after initiation of thiazolidinedione therapy in diabetes patients with established chronic heart failure. J Am Coll Cardiol 2003, 41:1394-1398.
3. Wang CH, Weisel RD, Liu PP. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003, 107:1350-1354.
4. Giles TF, Sanders GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic consideration. Cardiol Clin 2004, 22:553-568.
5. Drexler AJ, Nesto RW, Abrahamson MJ. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord 2005, 3:147-173.
6. Blaschke F, Spanheimer R, Khan M. Vascular effects of TZDs: new implications. Vascul Pharmacol 2006, 45:3-18.
7. Irons BK, Greene RS, Mazzolini TA. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006, 26:168-181.
8. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 2006, 45:19-28.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
10. Erdmann E, Charbonnel B, Wilcox RG. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007, 30:2773-2778.
11. Giles TD, Miller AB, Elkayam U. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445-452.
12. ACTOS® [package insert] 2007, Lincolnshire, IL, Takeda Pharmaceuticals America, Inc.
13. Erdmann E, Dormandy JA, Charbonnel B. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007, 49:1772-1780.
14. Nichols GA, Gullion CE, Koro CE. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
15. Levy D, Kenchaiah S, Larson MG. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
16. Roger VL, Weston SA, Redfield MM. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
17. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003, 26:2433-2441.
18. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. The Cilazapril-Captopril Multicenter Group. Cardiology 1995, 86(suppl 1):34-40.
19. Olsson LG, Swedberg K, Clark AL. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005, 26:778-793.